Probiomics becomes Bioxyne

16-Apr-2012 - Australia

Probiomics Limited has confirmed its name change to Bioxyne following its successful reverse takeover by Hunter Immunology. Managing Director and Chief Executive Officer, David Radford, said the name change signalled a step towards positioning the business for future growth in Australia and internationally with a strong corporate identity.  

“Our firm focus is to create shareholder value by commercialising our promising new therapy aimed at the major global medical market for chronic obstructive pulmonary disease (COPD) which includes emphysema and bronchitis.  The name change comes at a time when our focus is moving away from research and development to actively seeking to commercialise our first therapeutic asset currently known as HI-164OV,” he said.

Mr Radford confirmed Bioxyne was on track for the planned mid-year release of data from a 320 patient clinical trial of HI-164OV.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances